PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 2022-11-14 18:31:49

Tags for this article:

Health

Cancer treatments

Clinical medicine

Clinical research

Clinical trial

Design of experiments

Drug discovery

Pharmaceutical industry

National Cancer Institute

Pembrolizumab

the university of texas md anderson cancer center

pds biotechnology corporation

trial company

Versamune

Click the tags to see associated articles and topics

PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update. View article details on HISWAI: https://www.globenewswire.com/news-release/2022/11/14/2554872/37149/en/PDS-Biotech-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Business-Update.html

Excerpt

14, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of ...

Article found on: www.globenewswire.com

View Original Article